Oct 22 (Reuters) - Amgen ( AMGN ) will launch its

biosimilar version of Regeneron's blockbuster eye care

drug Eylea following a U.S. appeals court ruling in its favor on

Tuesday, an Amgen ( AMGN ) spokesperson said.

The U.S. Court of Appeals for the Federal Circuit rejected

Regeneron's request to temporarily block the launch during its

appeal of a related decision for Amgen ( AMGN ) in a patent case in West

Virginia.

Spokespeople for Regeneron did not immediately respond to a

request for comment on the decision. Eylea earned Regeneron

$5.89 billion in U.S. sales in 2023.